Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

AstraZeneca scores in final lung disease drug trials

The firm hopes it LAMA/LABA drug can take a big chunk from the $14bn COPD market

- PMLiVE

Catalent promotes Sharon Johnson within new organisation

She will be its senior VP of global quality and regulatory affairs

- PMLiVE

Galapagos and Janssen end inflammation alliance

Galapagos regains right to GLPG1690

Evolution of the wearable tech revolution

Stuart Goodman delves into the world of wearables, further analysing what role they play in pharma’s future.

Blue Latitude Health

- PMLiVE

Not all data is created equal

Aurélie Pols from Mind Your Privacy has written this guest blog post on data privacy and security, and specifically the risks of HIPAA or PII non-compliance, in both the USA...

Blue Latitude Health

- PMLiVE

AstraZeneca’s heart drug impresses, but bleeding risks a concern

Firm still hopes the new Brilinta data can help the medicine be a blockbuster

- PMLiVE

Imbruvica shines in combination trial

Showed significant increase in progression-free survival

- PMLiVE

Political tensions halt Fresenius’ Russian joint venture

Planned to combine subsidiary with Sistema and Zenitco’s CJSC Binnopharm

- PMLiVE

MISSION appoints Paul Wallace as chief business officer

Joins from Medivir where he was executive VP and head of business development

- PMLiVE

Baxter haemophilia drug clears phase III trial

BAX 817 shown to resolve more than 90% of acute bleeds

- PMLiVE

Merck faces another Bridion knockback

It is seven years since the FDA initially rejected it

Nelsons appoints new leadership team to US office

Pat Schneider, John Ende and Brad Baker join the firm

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links